JP2002539781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002539781A5 JP2002539781A5 JP2000606725A JP2000606725A JP2002539781A5 JP 2002539781 A5 JP2002539781 A5 JP 2002539781A5 JP 2000606725 A JP2000606725 A JP 2000606725A JP 2000606725 A JP2000606725 A JP 2000606725A JP 2002539781 A5 JP2002539781 A5 JP 2002539781A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- gln
- lys
- gly
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 claims 12
- 102000057471 human AKT3 Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 5
- 101150051155 Akt3 gene Proteins 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 239000003981 vehicle Substances 0.000 claims 3
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 102000011931 Nucleoproteins Human genes 0.000 claims 1
- 108010061100 Nucleoproteins Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12510899P | 1999-03-19 | 1999-03-19 | |
| US60/125,108 | 1999-03-19 | ||
| PCT/US2000/006574 WO2000056866A2 (en) | 1999-03-19 | 2000-03-14 | Akt-3 nucleic acids, polypeptides, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002539781A JP2002539781A (ja) | 2002-11-26 |
| JP2002539781A5 true JP2002539781A5 (enExample) | 2005-04-21 |
| JP4237945B2 JP4237945B2 (ja) | 2009-03-11 |
Family
ID=22418217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000606725A Expired - Fee Related JP4237945B2 (ja) | 1999-03-19 | 2000-03-14 | Akt核酸、ポリペプチドおよびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1144600B1 (enExample) |
| JP (1) | JP4237945B2 (enExample) |
| KR (1) | KR100700908B1 (enExample) |
| AT (1) | ATE402995T1 (enExample) |
| AU (1) | AU782448B2 (enExample) |
| BR (1) | BR0009170A (enExample) |
| CA (1) | CA2343074C (enExample) |
| CY (1) | CY1108459T1 (enExample) |
| DE (1) | DE60039677D1 (enExample) |
| DK (1) | DK1144600T3 (enExample) |
| ES (1) | ES2310515T3 (enExample) |
| HK (1) | HK1041288B (enExample) |
| IL (4) | IL141984A0 (enExample) |
| NO (1) | NO20014537L (enExample) |
| PT (1) | PT1144600E (enExample) |
| SI (1) | SI1144600T1 (enExample) |
| WO (1) | WO2000056866A2 (enExample) |
| ZA (1) | ZA200108414B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
| WO2000062605A1 (en) | 1999-04-16 | 2000-10-26 | Yale University | eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING |
| WO2000077190A2 (en) * | 1999-06-11 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
| JPWO2003063905A1 (ja) * | 2002-01-31 | 2005-05-26 | 株式会社東京大学Tlo | 免疫疾患の予防又は治療剤 |
| US20060051407A1 (en) * | 2003-06-27 | 2006-03-09 | Yoram Richter | Method of treating ischemia-reperfusion injury |
| US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
| EP1661581A1 (en) * | 2003-07-28 | 2006-05-31 | Osaka Industrial Promotion Organization | Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same |
| EP2599793A1 (en) * | 2008-05-29 | 2013-06-05 | Nuclea Biotechnologies, Inc. | Anti-phospho-akt antibodies |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| CN102985418B (zh) | 2010-07-02 | 2015-09-09 | 吉利德科学股份有限公司 | 凋亡信号调节激酶抑制剂 |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| ES2731602T3 (es) | 2014-09-24 | 2019-11-18 | Gilead Sciences Inc | Métodos para tratar la enfermedad hepática |
| CA3100432C (en) | 2014-12-23 | 2023-08-08 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| WO2020180886A1 (en) * | 2019-03-04 | 2020-09-10 | The Trustees Of The University Of Pennsylvania | Neuroprotective gene therapy targeting the akt pathway |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08109197A (ja) * | 1994-10-07 | 1996-04-30 | Sumitomo Electric Ind Ltd | 白血病腫瘍拒絶抗原ペプチド |
| DE69633186T2 (de) * | 1995-11-16 | 2005-08-18 | Novartis Ag | Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren |
| US5958773A (en) * | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
| GB9828375D0 (en) * | 1998-12-22 | 1999-02-17 | Janssen Pharmaceutica Nv | Human akt-3 |
| US6043090A (en) * | 1999-03-23 | 2000-03-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Akt-2 expression |
| CA2383592A1 (en) * | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| WO2000077190A2 (en) * | 1999-06-11 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt |
-
2000
- 2000-03-14 EP EP00917899A patent/EP1144600B1/en not_active Expired - Lifetime
- 2000-03-14 AT AT00917899T patent/ATE402995T1/de active
- 2000-03-14 JP JP2000606725A patent/JP4237945B2/ja not_active Expired - Fee Related
- 2000-03-14 WO PCT/US2000/006574 patent/WO2000056866A2/en not_active Ceased
- 2000-03-14 BR BR0009170-7A patent/BR0009170A/pt not_active Application Discontinuation
- 2000-03-14 DK DK00917899T patent/DK1144600T3/da active
- 2000-03-14 PT PT00917899T patent/PT1144600E/pt unknown
- 2000-03-14 CA CA2343074A patent/CA2343074C/en not_active Expired - Fee Related
- 2000-03-14 IL IL14198400A patent/IL141984A0/xx unknown
- 2000-03-14 ES ES00917899T patent/ES2310515T3/es not_active Expired - Lifetime
- 2000-03-14 AU AU38802/00A patent/AU782448B2/en not_active Ceased
- 2000-03-14 IL IL14551400A patent/IL145514A0/xx unknown
- 2000-03-14 SI SI200031007T patent/SI1144600T1/sl unknown
- 2000-03-14 DE DE60039677T patent/DE60039677D1/de not_active Expired - Lifetime
- 2000-03-14 HK HK02102803.1A patent/HK1041288B/en not_active IP Right Cessation
- 2000-03-14 KR KR1020017011960A patent/KR100700908B1/ko not_active Expired - Fee Related
-
2001
- 2001-09-18 NO NO20014537A patent/NO20014537L/no unknown
- 2001-09-20 IL IL145514A patent/IL145514A/en not_active IP Right Cessation
- 2001-10-12 ZA ZA200108414A patent/ZA200108414B/xx unknown
-
2008
- 2008-03-18 IL IL190270A patent/IL190270A/en not_active IP Right Cessation
- 2008-10-27 CY CY20081101217T patent/CY1108459T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002539781A5 (enExample) | ||
| JP5451960B2 (ja) | 酵母におけるhpv45l1の最適化された発現 | |
| CN115246874B (zh) | 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用 | |
| KR0164215B1 (ko) | 사람 유두종바이러스 제16형 e7 단백질상의 면역원성 서열을 갖는 폴리펩타이드 | |
| WO2022206222A1 (zh) | 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用 | |
| JP2008536483A5 (enExample) | ||
| JP2006501825A5 (enExample) | ||
| JP2024180560A5 (enExample) | ||
| CA2343074A1 (en) | Akt nucleic acids, polypeptides, and uses thereof | |
| CN114891119A (zh) | 降解PD-L1的生物大分子靶向蛋白水解嵌合体BioPROTAC及其制备方法和应用 | |
| CN101062952B (zh) | 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用 | |
| CN114560915A (zh) | 一种改造的高滴度SARS-CoV-2假病毒 | |
| CN106164090B (zh) | TRAIL穿膜肽样突变体MuR6、制备方法及应用 | |
| US10548973B2 (en) | Polypeptide carrier for presenting target polypeptide and uses thereof | |
| Günther et al. | Protein and peptide delivery via engineered polyomavirus‐like particles | |
| Rueda et al. | Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles | |
| CA2098926A1 (en) | Medicaments for the treatment of papillomavirus diseases | |
| US20090155853A1 (en) | Non-viral gene delivery complex | |
| JP2003507029A5 (enExample) | ||
| JPS6312299A (ja) | ポリペプチドの生産のための発現ベクタ−、ポリペプチドの交換発現法、発現ベクタ−を含有する宿主、それによりつくられた生産物 | |
| CN102643349B (zh) | 携带乙肝病毒抗原表位的重组嵌合蛋白及其制备 | |
| CN106459172A (zh) | 一种TRAIL双靶点突变蛋白MuR5S4TR、其制备方法及其应用 | |
| JP2004518410A5 (enExample) | ||
| KR100785397B1 (ko) | 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신 | |
| CN119798408B (zh) | 一种识别hpv多抗原表位的tcr及其编码序列 |